642091-68-7

Usage

Uses

Used in Bioconjugation:
Azido-PEG4-NHBoc is used as a bioconjugation agent for the attachment of biomolecules to other molecules or surfaces. The azide group in the molecule allows for efficient and specific labeling of biomolecules through Click Chemistry, enabling the creation of novel conjugates with improved properties and functionalities.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Azido-PEG4-NHBoc is used as a component in the development of drug delivery systems. The PEGylation of drugs using this reagent can enhance their solubility, stability, and bioavailability, leading to improved therapeutic outcomes. Additionally, the Boc-protected amino group allows for the controlled release of the drug by deprotection under specific conditions.
Used in Materials Science:
Azido-PEG4-NHBoc is used as a building block in the synthesis of novel materials with tailored properties. The reactivity of the azide group with alkyne-containing monomers enables the creation of well-defined polymers and copolymers with specific characteristics, such as enhanced biocompatibility, improved mechanical properties, or controlled degradation rates.
Used in Chemical Synthesis:
In the field of chemical synthesis, Azido-PEG4-NHBoc serves as a versatile intermediate for the preparation of various PEGylated compounds. The Boc-protected amino group can be selectively deprotected to introduce a free amine, which can then be further functionalized or used in the synthesis of more complex molecules.
Used in Diagnostics:
Azido-PEG4-NHBoc is used as a labeling agent in the development of diagnostic tools, such as imaging agents and biosensors. The azide group can be selectively reacted with alkyne-containing probes or markers, allowing for the specific and efficient labeling of target molecules or surfaces.

Upstream product

• 55400-73-2 ((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl) dimethanesulfonate 
• 101187-39-7 1,11-diazido-3,6,9-trioxaundecane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 86770-74-3 11-amino-3,6,9-trioxaundecanol 
• 86770-67-4 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethanol 
• 65883-12-7 2-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}ethyl methanesulfonate 
• 106984-09-2 2-<2-<2-<2-<(tert-Butoxycarbonyl)amino>ethoxy>ethoxy>ethoxy>ethanol 
• 134179-38-7 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethylamine 
• 112-60-7 Tetraethylene glycol 
• 37860-51-8 tetraethylene glycol di(p-toluenesulfonate) 
• 77544-60-6 p-toluenesulfonic acid 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl ester 

Downstream Products

• 101187-40-0 1-Boc-amine-11-amino-3,6,9-trioxaundecane 

Relevant academic research and scientific papers

Design and synthesis of small molecule-conjugated photoaffinity nanoprobes for a streamlined analysis of binding proteins

We designed and synthesized a set of photoaffinity nanoprobes, which multivalently display a small molecule ligand and a photoreactive group on gold nanoparticles. Due to the typically hydrophobic nature of these two functional groups, a hydrophilic spacer was additionally introduced to co-functionalize the nanoprobes to maintain their dispersibility in aqueous buffer solutions. Photoaffinity labeling studies using the nanoprobes composed of different ratios of three functional groups showed that including high density of the spacer group attenuates crosslinking efficiency. Comparative analysis of the reactivity among three major photoreactive groups suggested that unlike in the context of conventional photoaffinity probes, arylazide group enables the most selective crosslinking of a model small molecule binding protein.

RADIOLABELLED TARGETING LIGANDS

The present invention relates to compounds that are useful as radioimaging agents and radiopharmaceuticals. The compounds may be coordinated with a radionuclide and may be useful in diagnostic imaging and radiotherapy. The invention also relates to method

ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications

Radioiodinated 4-(p-Iodophenyl) Butanoic Acid-Modified Estradiol Derivative for ER Targeting SPECT Imaging

Overexpression of estrogen receptors (ERs) is one of the important characteristics of most breast cancers. We aim to develop a new type of ER-specific radioiodine-labeled estrogen derivative ([131I]IPBA-EE), which was modified with an albumin-specific lig

Bioorthogonal Ligation and Cleavage by Reactions of Chloroquinoxalines with ortho-Dithiophenols

A bioorthogonal ligation and cleavage method via reactions of chloroquinoxalines (CQ) and ortho-dithiophenols (DT) is presented. Double nucleophilic substitutions of ortho-dithiophenols to chloroquinoxalines provide conjugates containing tetracyclic benzo[5,6][1,4]dithiino[2,3-b]quinoxaline with strong built-in fluorescence together with release of the other functional molecules. Three cleavable linkers were designed and successfully used in release of the molecules containing biotin from the protein conjugates. The CQ-DT bioorthogonal reactions can be applied for the bioorthogonal ligations, bioorthogonal cleavages, and trans-tagging of proteins, and show advantages of readily accessible unnatural orthogonal groups, appealing reaction kinetics (k2≈1.3 m?1 s?1), excellent biocompatibility of orthogonal groups, and high stability of conjugates. This complements previous bioorthogonal reactions and is a new route for protein-fishing applications and in-gel fluorescence analysis.

Targeted and modular architectural polymers employing bioorthogonal chemistry for quantitative therapeutic delivery

There remain several key challenges to existing therapeutic systems for cancer therapy, such as quantitatively determining the true, tissue-specific drug release profile in vivo, as well as reducing side-effects for an increased standard of care. Hence, it is crucial to engineer new materials that allow for a better understanding of the in vivo pharmacokinetic/pharmacodynamic behaviours of therapeutics. We have expanded on recent "click-to-release" bioorthogonal pro-drug activation of antibody-drug conjugates (ADCs) to develop a modular and controlled theranostic system for quantitatively assessing site-specific drug activation and deposition from a nanocarrier molecule, by employing defined chemistries. The exploitation of quantitative imaging using positron emission tomography (PET) together with pre-targeted bioorthogonal chemistries in our system provided an effective means to assess in real-time the exact amount of active drug administered at precise sites in the animal; our methodology introduces flexibility in both the targeting and therapeutic components that is specific to nanomedicines and offers unique advantages over other technologies. In this approach, the in vivo click reaction facilitates pro-drug activation as well as provides a quantitative means to investigate the dynamic behaviour of the therapeutic agent.

FUSED HETEROCYCLIC BENZODIAZEPINE DERIVATIVES AND USES THEREOF

The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

DC-SIGN ANTIBODY DRUG CONJUGATES

Provided herein are antibodies to DC-SIGN, conjugates of DC-SiGN antibodies, and DC-SiGN antibody fusion proteins and the use of such antibodies, conjugates, and fusion proteins for the treatment of diseases such as cancer.

Assessing Interactions between Helical Aromatic Oligoamide Foldamers and Protein Surfaces: A Tethering Approach

Helically folded aromatic foldamers may constitute suitable candidates for the ab initio design of ligands for protein surfaces. As preliminary steps toward the exploration of this hypothesis, a tethering approach was developed to detect interactions between a protein and a foldamer by confining the former at the surface of the latter. Cysteine mutants of two therapeutically relevant enzymes, CypA and IL4, were produced. Two series of ten foldamers were synthesized bearing different proteinogenic side chains and either a long or a short linker functionalized with an activated disulfide. Disulfide exchange between the mutated cysteines and the activated disulfides yielded 20 foldamer-IL4 and 20 foldamer-CypA adducts. Effectiveness of the reaction was demonstrated by LC-MS, by MS analysis after proteolytic digestion, and by 2D NMR. Circular dichroism then revealed diastereoselective interactions between the proteins and the foldamers confined at their surface which resulted in a preferred handedness of the foldamer helix. Helix sense bias occurred sometimes with both the short and the long linkers and sometimes with only one of them. In a few cases, helix handedness preference is found to be close to quantitative. These cases constitute valid candidates for structural elucidation of the interactions involved.

NOVEL BENZODIAZEPINE DERIVATIVES AND USES THEREOF

The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.